68/100
✓ Peer-reviewed
alzhub usefulness score 68 out of 100.
·
Neurology
·
2025-12-03
At baseline, 2,279 dementia-free participants with available blood samples were included (median age 72 (interquartile range, 61-81) years; 62% female). 4 key findings →
Design: cohort
Participants: 2,279
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
68/100
✓ Peer-reviewed
alzhub usefulness score 68 out of 100.
·
JAMA Neurology
·
2026-07-01
The BioFINDER-2 main cohort included 872 participants, with an additional 156 participants in the Knight ADRC cohort for independent validation. 2 key findings →
Design: cohort
Participants: 1,028
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
Baseline plasma GFAP could detect abnormal CSF Aβ42/40 and CSF Aβ42/T-tau with an AUC of 0.79 (95% CI 0.72-0.86) and 0.80 (95% CI 0.72-0.86), respectively. 3 key findings →
Design: longitudinal study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
68/100
✓ Peer-reviewed
alzhub usefulness score 68 out of 100.
·
JAMA neurology
·
2019-03-01
Cognitive testing follow-up occurred for 1 to 18 years (mean [SD], 0.98 [2.25] years); autopsy-verified diagnoses were available for 120 of 845 participants with diseases (14.2%). 2 key findings →
Design: case-control study
Participants: 913
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
68/100
✓ Peer-reviewed
alzhub usefulness score 68 out of 100.
·
Neurology
·
2023-05-24
In a community-based cohort of 70-year olds, P-NfL was associated with both prevalent and incident CKD, while CSF and/or imaging measures did not differ by CKD status. 3 key findings →
Design: cohort study
Participants: 744
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
68/100
✓ Peer-reviewed
alzhub usefulness score 68 out of 100.
·
Neurology
·
2024-06-03
Our study suggests a possible utility of plasma Aβ42/40, P-tau181, and P-tau231 as a noninvasive biomarkers to assess amyloid copathology in DLB, and plasma GFAP and NfL as monitoring biomarkers for cognitive symptoms in DLB. 4 key findings →
Design: cohort study
Participants: 89
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
68/100
✓ Peer-reviewed
alzhub usefulness score 68 out of 100.
·
Neurology
·
2018-02-02
Baseline biomarkers largely do not predict risk for developing ARIA-E. ARIA-E was associated with significant longitudinal changes in several biomarkers, with larger reductions in amyloid PET and CSF p-tau and t-tau concentrations, and paradoxically greater hippocampal volume reduction and ventricular enlargement, suggesting that ARIA-E in bapineuzumab-treated cases may be related to increased Aβ efflux from the brain and affecting downstream pathogenic processes. 4 key findings →
Design: longitudinal study
Participants: 1,512
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Baseline plasma VEGFA and PGF each showed a significant interaction with amyloid burden on prospective cognitive decline. 5 key findings →
Design: longitudinal study
Participants: 317
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
68/100
✓ Peer-reviewed
alzhub usefulness score 68 out of 100.
·
Neurology
·
2020-05-01
This study shows that PUTG component scores were significantly associated with diagnostic group and AD biomarkers, a finding that was more pronounced in APOE ε4 carriers. 5 key findings →
Design: longitudinal study
Participants: 689
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Cerebrospinal fluid biomarkers may be useful to monitor the effects of novel disease-modifying anti-Aβ drugs in clinical trials. 3 key findings →
Design: clinical trial
Participants: 19
Evidence: high
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
Our results suggest that diet may be a powerful environmental factor that modulates Alzheimer disease risk through its effects on central nervous system concentrations of Aβ42, lipoproteins, oxidative stress, and insulin. 2 key findings →
Design: randomized controlled trial
Participants: 29
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
68/100
✓ Peer-reviewed
alzhub usefulness score 68 out of 100.
·
JAMA neurology
·
2023-12-01
In this randomized clinical trial, BIIB080 reduced tau biomarkers, including CSF t-tau, CSF p-tau181, and tau PET, which is associated with cognitive decline, in participants with mild AD. 5 key findings →
Design: clinical trial
Participants: 13
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
68/100
✓ Peer-reviewed
alzhub usefulness score 68 out of 100.
·
Neurology
·
2024-12-13
Of 47 participants enrolled (mean age = 73.8 years; 43% female), 1 dropped out before treatment initiation and 6 before completion, including 2 in the nicotinamide and 4 in the placebo arm. 4 key findings →
Participants: 47
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
68/100
✓ Peer-reviewed
alzhub usefulness score 68 out of 100.
·
Nature aging
·
2023-05-18
Blood-based biomarkers hold great promise to revolutionize the diagnostic and prognostic work-up of Alzheimer's disease (AD) in clinical practice. 5 key findings →
Design: longitudinal study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
In multivariate analyses, baseline age, University of Pennsylvania Smell Inventory Test (UPSIT) scores, CSF amyloid - (Aβ 42 ) to t-tau ratio, and APOE status were associated with change in MoCA scores over time. 5 key findings →
Design: cohort study
Participants: 390
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Moreover, biomarker plasma levels and rates of change over time of participants who developed Alzheimer's disease dementia during follow-up were compared with age and sex-matched dementia-free control subjects. 5 key findings →
Participants: 549
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
Elecsys CSF biomarker assays may provide reliable alternatives to PET in Alzheimer's disease diagnosis. 3 key findings →
Participants: 277
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Brain iron elevation is implicated in Alzheimer's disease (AD) pathogenesis, but the impact of iron on disease outcomes has not been previously explored in a longitudinal study. 3 key findings →
Design: longitudinal study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
68/100
✓ Peer-reviewed
alzhub usefulness score 68 out of 100.
·
Neurology
·
2022-08-26
The risk of mild cognitive impairment (MCI) or dementia in individuals with subjective cognitive decline (SCD) and biomarkers indicating Alzheimer disease (AD) pathology in comparison with individuals with SCD without biomarker evidence for AD is critical to delineate the potential role of biomarker assessment in this group. 4 key findings →
Design: meta-analysis
Evidence: high
Full summary, score breakdown and related studies →
Original source
Full text may need a subscription
Plasma amyloid-β (Aβ) peptide levels have been examined as a low-cost accessible marker for risk of incident Alzheimer's disease (AD) and dementia, but results have varied between studies. 4 key findings →
Participants: 2,189
Evidence: low
Full summary, score breakdown and related studies →
Original source
Free full text
68/100
✓ Peer-reviewed
alzhub usefulness score 68 out of 100.
·
Neurology
·
2025-12-09
A total of 716 individuals were included in the analysis: 413 cognitively unimpaired (CU) participants (58.6% female; mean age = 70.6 years, SD = 7.9) and 303 cognitively impaired (CI) participants (54.7% female; mean age = 73.2 years, SD = 7.4). 5 key findings →
Design: longitudinal study
Participants: 716
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
Free full text
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that is characterized by amyloid-beta (Aβ) accumulation and neuroinflammation. 4 key findings →
Design: clinical trial
Participants: 21
Evidence: high
Full summary, score breakdown and related studies →
Original source
Free full text
68/100
✓ Peer-reviewed
alzhub usefulness score 68 out of 100.
·
Nature medicine
·
2026-07-01
Detection of Alzheimer's disease (AD) before the development of clinical symptoms is critical for enabling the use of new treatments. 2 key findings →
Participants: 551
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
MES-defined cognitive impairment (≤-2 standard deviation [SD] deviation after adjustment for demographics) was identified in 12.4% of participants. 5 key findings →
Design: longitudinal study
Evidence: moderate
Full summary, score breakdown and related studies →
Original source
P-tau181 (odds ratio [OR] 2.06, 95% confidence interval [CI] 1.41-3.00, p < 0.001), p-tau217 (OR 1.70, 95% CI 1.10-2.61, p = 0.016), and t-tau (OR 1.44, 95% CI 1.08-1.92, p = 0.012) were associated with appetite change. 5 key findings →
Design: cross-sectional
Participants: 1,005
Evidence: low
Full summary, score breakdown and related studies →
Original source
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor,
and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a
scientist can tell a landmark trial from a conference abstract without having to already know the
difference. Every point comes from one of 20 components, all of them printed on the study itself,
so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomized / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multicenter collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we
could not verify current impact factors from a source we control, and an invented one would be
worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science,
Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed
journal. A separate part scores how much the journal's own papers are cited, which tells the
tier-3 journals apart.
Two rules we don't bend. First, we never fill in a
missing value: if a record does not state a sample size or a design, that component scores
zero, and if we simply have no data for a part, such as a citation count, that part is left out and
the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed
article is capped at 16/100 and carries a warning chip — so a conference abstract or
a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not
work — above an early positive finding. Someone deciding whether to buy a supplement is served by
that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is
reproducible: the same file always yields the same numbers.
See the whole rubric drawn out →
— four charts covering all 32,580 studies: how the scores are spread and where the cap
bites, which of the 20 components the library is strong and weak on, which subjects rest on
stronger evidence, and what kinds of study each subject is actually built from.